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licenseVitrectomy for diabetic macular edema; where are we?Diabetic retinopathy is the leading cause of visual impair-
ment in the working age group mainly due to diabetic macular
edema (DME).1,2
As the incidence of diabetes is increasing in human pop-
ulations, the visual burden of DME is expected to expand. The
standard treatment for DME has been macular laser photo-
coagulation3 for almost two decades but has shifted to intra-
vitreal injection of anti-VEGF agents over the past decade.
Although the intravitreal injection of these drugs and even
steroids has been shown to be superior to macular laser pho-
tocoagulation,4e10 there is much to be desired in the treatment
of DME.
It has been suggested that attached vitreous may have an
adverse effect on the clinical course of DME. Posterior vit-
reous detachment has been reported to be less common in eyes
with DME and that attached vitreous may diminish the benefit
of intravitreal steroid therapy.11 On this basis, some authors
have suggested pars plana vitrectomy and removal of posterior
hyaloid with or without ILM removal for treatment of DME.
The DRCR network has reported the results of vitrectomy in
cases of vitreomacular traction associated with diabetic retin-
opathy.12 The macular thickness significantly decreased in most
eyes. Between 28% and 49% of eyes experienced improvement
of visual acuity, whereas in 13%e31% the visual acuity wors-
ened. In patients without vitreomacular traction, with or without
epiretinal membranes, however, the results of vitrectomy have
been more variable and the majority of studies have reported
non-significant visual improvement despite initial structural
improvement. Simunovic et al13 published a systematic review
and meta-analysis on the outcomes of vitrectomy for DME and
concluded that there is little evidence to support vitrectomy as a
treatment for diabeticmacular edema in the absence of epiretinal
membrane or vitreomacular traction and that although vitrec-
tomy appears to be superior to laser in its effects on retinal
structure at 6 months, no such benefit has been proven at 12
months. Similar results were obtained by Jackson et al14 in their
recent systematic review, meta-analysis, and synthesis of safety
literature. They did not identify any major safety concerns.
In this issue, Ghassemi et al have studied a group of 12 eyes
with non-tractional epiretinal membranes associated withr review under responsibility of the Iranian Society of Ophthalmology.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).DME refractory to at least 2 intravitreal injections of bev-
acizumab and one injection of triamcinolone acetonide.
Vitrectomy, membranectomy, and ILM peeling was performed
in these patients which resulted in significant reduction of
central macular thickness without a parallel significant
improvement in visual acuity. These results are well based in
literature as mentioned previously. The authors are to be
commended for their study of the subgroup of eyes with non-
tractional epiretinal membranes specifically, which has not
been clearly reported in literature.
Despite these findings, the role of vitrectomy in the treat-
ment of DME without vitreomacular traction cannot be
entirely ruled out. It should be considered that in many cases
reported in literature, including the cases studied by Ghassemi
et al, vitrectomy has been performed on eyes with long-
standing macular edema. It is conceivable that such eyes have
already sustained marked structural damage which makes
them refractory to any kind of treatment including vitrectomy.
In other words, these eyes may be refractory to vitrectomy for
the very reason that they are refractory to anti-VEGF agents. It
is quite likely that vitrectomy and its resultant decrease in
macular edema would lead to vision improvement in eyes
without much structural damage. In fact, two studies have
already demonstrated a correlation between the pre-vitrectomy
integrity of outer retina (external limiting membrane and
ellipsoid zone) and the potential for vision improvement after
vitrectomy.15,16 Adequately sized randomized clinical trial are
needed to elucidate the role of vitrectomy on the amount and
duration of visual improvement in eyes with preserved outer
retina as compared to other treatment modalities.References
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